Microbira at the 9th AMR Conferece, BAsel, Switzerland, 25-36th Feb 2025
Last week, we had the privilege of attending the AMR Conference in Basel. A key gathering of experts, innovators, and healthcare professionals dedicated to tackling antimicrobial resistance. The event brought together everyone from SMEs, to leading pharmaceutical companies, academia, as well as public institutions to explore strategies and address the unique challenges within the innovation ecosystem in developing and bringing new antimicrobial treatments and diagnostics to market.
Reflection
Microbira was proud to contribute to these discussions, with our CEO, Marianne Ismail, presenting in the Technology Corner – Diagnostics Session. The presentation focused on Combating AMR with Rapid and Reagent-Free Fluconazole Resistance Detection Using MAAP-IR. The presentation highlighted how our MAAP-IR software is revolutionising the way fluconazole resistance is detected. By using reagent-free FTIR spectroscopy combined with AI algorithms, our technology enables rapid, precise identification of fluconazole-resistant in under 5 minutes. Furthermore, this innovation is a novel step in optimising antifungal stewardship and improving patient outcomes.
CEO quote:
“One of the best features of the AMR conference in Basel is its size. It is well attended and well organised and there is lots of space for meetings and discussions. It was great to see diagnostics featuring strongly.
Several speakers made the point that there needs to be a focus on the substantial costs in patient care of NOT using diagnostics to optimise timely treatments and prevent more AMR. Promotion of diagnostics through measurements of their role in downstream impacts is a key step-in longer-term cost saving through avoiding patients becoming in-patients and shorter patient stays in hospitals.
For LMICs accessibility of low-cost diagnostics is recognised as essential in the AMR battle.”
Conclusion
In summary, the conference underscored the urgency of AMR and the need for collaborative efforts across industries. From discussions on novel drug development to improving diagnostic pathways, there was a clear message. Innovation, investment, and strategic partnerships are essential in the fight of rising AMR.
In addition, attending the AMR Conference reinforced our commitment to providing cutting-edge diagnostic solutions that support antimicrobial stewardship. We are excited to continue engaging with partners across healthcare, pharma, and research to drive meaningful change in AMR detection and management. We extend our thanks to BEAM Alliance and also bamconn GmbH for organising the conference and the opportunity to present and network. Microbira are already looking forward to next year’s event.
